Product Information
LISDEXAMFETAMINE 20 MG TB CHEW is a generic product labeled by SpecGx LLC, priced at $4.3379 per EA under NDC 00406512501. Its NADAC has been published 56 times since Sep 10, 2025.
FDA first approved this application on Dec 17, 2024. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
20 mg/1
Manufacturer
SpecGx LLCNDC
00406512501
Classification
Generic
Dosage Form
TABLET, CHEWABLE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LISDEXAMFETAMINE DIMESYLATEApproval Type
Generic (ANDA)
FDA Application
ANDA218850FDA Approved
12/17/2024
TE Code
AB
On Market Since
12/17/2024
Pharmacological Classes
Price Statistics
The NADAC for LISDEXAMFETAMINE 20 MG TB CHEW has been published 56 times since Sep 10, 2025, and over the history we have for it it has declined 39.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $4.3379 per EA |
|---|---|
| All-time high | $7.1531 (Sep 10, 2025) |
| All-time low | $4.2936 (Jul 22, 2026) |
| 52-week high | $6.6501 |
| 52-week low | $4.2936 |
| Median price | $4.5521 |
| Average price | $5.1641 |
| Largest weekly change | -13.0% (Feb 18, 2026) |
| Weeks tracked | 56 |
| Tracking since | Sep 10, 2025 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Lisdexamfetamine Dimesylate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
SpecGx LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Lisdexamfetamine Dimesylate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Central Nervous System Stimulant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LISDEXAMFETAMINE 20 MG TB CHEW?
The current National Average Drug Acquisition Cost (NADAC) for LISDEXAMFETAMINE 20 MG TB CHEW, manufactured by SpecGx LLC, is $4.3379 per EA (NDC 00406512501), effective Sep 30, 2026.
How has the price of LISDEXAMFETAMINE 20 MG TB CHEW changed over time?
Over the history we have for it, the NADAC for LISDEXAMFETAMINE 20 MG TB CHEW has declined 39.4%. It has been tracked across 56 weekly CMS publications since Sep 10, 2025.
What are the highest and lowest recorded NADAC prices for LISDEXAMFETAMINE 20 MG TB CHEW?
Since Sep 10, 2025, the NADAC for LISDEXAMFETAMINE 20 MG TB CHEW has ranged from a low of $4.2936 (Jul 22, 2026) to a high of $7.1531 (Sep 10, 2025), with a median of $4.5521 per EA.
Are there cheaper alternatives to LISDEXAMFETAMINE 20 MG TB CHEW?
No other NADAC-published product currently shares the active ingredient and strength of LISDEXAMFETAMINE 20 MG TB CHEW in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures LISDEXAMFETAMINE 20 MG TB CHEW?
LISDEXAMFETAMINE 20 MG TB CHEW (NDC 00406512501) is labeled by SpecGx LLC, and CMS classifies it as a generic product.